Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/12233
Title: | Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission | Authors: | BUYSE, Marc Michiels, Stefan Squifflet, Pierre Lucchesi, Kathryn J. Hellstrand, Kristoffer Brune, Mats L. Castaigne, Sylvie Rowe, Jacob M. |
Issue Date: | 2011 | Publisher: | FERRATA STORTI FOUNDATION | Source: | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96 (8). p. 1106-1112 | Abstract: | Background In trials designed to evaluate new therapies for hematologic malignancies, end points such as leukemia-free survival are often used as surrogates for overall survival in acute leukemia. We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied to remission maintenance therapy for acute myeloid leukemia. Design and Methods Data were analyzed from a randomized Phase III trial of remission maintenance immunotherapy with histamine dihydrochloride plus low-dose interleukin-2 versus no treatment in adults with acute myeloid leukemia. A two-stage surrogate validation model was applied in which correlations between Kaplan-Meier estimates of leukemia-free survival and overall survival, and between log hazard ratios reflecting treatment effects were analyzed. Country of patient enrollment was the unit of analysis. Results Kaplan-Meier estimates of overall survival at 36, 48, and 60 months and leukemia-free survival at 24 months were reasonably correlated (R(2) ranging from 0.44 to 0.84) both for the overall (n=320) and first complete remission (n=261) populations. The effects of histamine dihydrochloride/interleukin-2 on log hazard ratios for leukemia-free survival and overall survival were well correlated (R(2)=0.88-0.93). Conclusions The significant correlations between overall survival and the surrogate end point (leukemia-free survival) and between the effect of histamine dihydrochloride/interleukin-2 on leukemia-free survival and overall survival satisfy the two-stage surrogate validation model. (ClinicalTrials.gov Identifier: NCT00003991) | Notes: | [Buyse, M; Squifflet, P] IDDI, B-1340 Louvain, Belgium [Buyse, M] Hasselt Univ, Ctr Stat, I BioStat, Diepenbeek, Belgium [Michiels, S] Inst Jules Bordet, B-1000 Brussels, Belgium [Lucchesi, KJ] MedVal Sci Informat Serv LLC, Skillman, NJ USA [Hellstrand, K; Brune, ML] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden [Castaigne, S] Hop Andre Mignot, Le Chesnay, France [Rowe, JM] Rambam Med Ctr, Haifa, Israel [Rowe, JM] Technion Israel Inst Technol, Haifa, Israel marc.buyse@iddi.com | Keywords: | leukemia-free survival; overall survival; immunotherapy; statistical analyses; clinical trial interpretation;leukemia-free survival; overall survival; immunotherapy; statistical analyses; clinical trial interpretation | Document URI: | http://hdl.handle.net/1942/12233 | ISSN: | 0390-6078 | e-ISSN: | 1592-8721 | DOI: | 10.3324/haematol.2010.039131 | ISI #: | 000294722700007 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2012 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
buyse 1.pdf | Published version | 405.73 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
28
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
31
checked on Apr 22, 2024
Page view(s)
68
checked on Sep 7, 2022
Download(s)
110
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.